. Author manuscript; available in PMC: 2016 May 1.

Published in final edited form as: Heart Fail Rev. 2015 May;20(3):283–290. doi: 10.1007/s10741-014-9467-2

Table 1.

Comparison of mineralocorticoid dose in major clinical trials in conjunction with ACE-I and β-blockers

	RALES	EPHESUS	EMPHASIS-HF
Mean LVEF (%)	25	33	26
RF exclusion	sCr >2.5 mg/dL	sCr >2.5 mg/dL	eGFR <30 mL/min per 1.73 m²
ACE-I/ARB (%)	95	86	94
β-Blocker (%)	11	75	87
Mean MRA dose (mg/day)	26	43.5	39
Serum K >6 meq/L (%)	2	5.5	2.5

ACE-I angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, LVEF left ventricular ejection fraction, RF renal function, sCr serum creatinine, eGFR estimated glomerular filtration rate, MRA mineralocorticoid receptor blocker, serum K serum potassium